Here are four key statistics:
1. Through 2020, orphan drugs’ annual sales are likely to increase 12 percent each year.
2. The average annual price tag for orphan drugs totaled $111,820 in 2014. Comparatively, mainstream drugs cost $23,331, on average, that year.
3. Excluding genetics, estimates expect global orphan drug sales to comprise slightly more than 20 percent of all drug sales.
4. The Department of Health sent a report to Congress in December 2016 which found orphan drugs cost $1 billion to develop, compared to $2.6 billion for mass market drugs.
More articles on quality & infection control:
North America leads global infection control market with 39.5% market share: 5 takeaways
ASC Quality Collaboration report: 9 key benchmarks from Q3 2016
Trump’s take on pharmaceutical companies: ‘Getting away with murder’
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
